Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

ClinicalTrials.gov ID: NCT07675629

Public ClinicalTrials.gov record NCT07675629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV

Study identification

NCT ID: NCT07675629
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Worcester HIV Vaccine; Industry
Enrollment: 126 participants

Conditions and interventions

Conditions

HIV Prevention

Interventions

PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)) Biological
PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)) Biological
Alhydrogel adjuvant Biological
GLA-SE adjuvant Biological
Placebo for DNA Vaccines, Protein Vaccines and Adjuvants Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2026
Primary completion: Aug 30, 2028
Completion: Jul 31, 2029
Last update posted: Jun 29, 2026

2026 – 2029

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Brigham and Women's Hospital	Boston	Massachusetts	02115	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07675629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 29, 2026 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07675629 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →